Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Influence of Delayed Receipt of Effective Antimicrobial Therapy on Clinical Outcome

Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-don Oh; Eui-Chong Kim; Kang-Won Choe
September 2003
Clinical Infectious Diseases;9/15/2003, Vol. 37 Issue 6, p745
Academic Journal
Evaluates the risk factors for mortality and influence of delayed receipt of antimicrobial therapy on clinical outcome of Pseudomonas aeruginosa bacteremia. Inclusion of severe sepsis and pneumonia as risk factors for mortality; Association between delay in starting effective antimicrobial therapy for P. aeruginosa bacteremia and higher mortality.


Related Articles

  • Combination treatment shows no reduced mortality in P. aeruginosa.  // Infectious Disease News;Aug2013, Vol. 26 Issue 8, p25 

    The article discusses the mortality risk in patients with Pseudomonas aeruginosa bloodstream infections that references a study by researcher from the Spanish Network for Research in Infectious disease, that found the recommended treatment with combination antimicrobial did not reduce the risk.

  • Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Peña, Carmen; Suarez, Cristina; Ocampo-Sosa, Alain; Murillas, Javier; Almirante, Benito; Pomar, Virginia; Aguilar, Manuela; Granados, Ana; Calbo, Esther; Rodríguez-Baño, Jesús; Rodríguez, Fernando; Tubau, Fe; Oliver, Antonio; Martínez-Martínez, Luis // Clinical Infectious Diseases;Jul2013, Vol. 57 Issue 2, p208 

    Empirical combination therapy is recommended for patients with known or suspected Pseudomonas aeruginosa (PA). A post hoc analysis of patients with PA bloodstream infections suggests that treatment with combination antimicrobial therapy did not reduce the mortality risk compared with single-drug...

  • Nebulized Colistin in the Treatment of Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Kwa, Andrea L. H.; Loh, ChinSiew; Low, Jenny G. H.; Kurup, Asok; Tam, Vincent H. // Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, p754 

    Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably...

  • Identification of Beta-Lactamase-Producing Pseudomonas aeruginosa with Multiple Antibiotic Resistances. Fazzeli, Hossein; Faghri, Jamshid; Kabiri, Payam; Fatahibafghi, Mehdi; Arabestani, Mohammad Reza // Journal of Isfahan Medical School;11/14/2011, Vol. 29 Issue 154, p1 

    Background: The clinical use of antibiotics in treatment of Pseudomonas aeruginosa infections causes resistant to multiple drugs increasingly. P. aeruginosa could produce beta lactamase enzyme to beta lactam antibiotics that causes many problems. The purpose of this study is analysis of the...

  • Anti-infectives/hydrocarbons/glucocorticoids.  // Reactions Weekly;5/12/2012, Issue 1401, p6 

    The article describes the case of a 23-year-old woman and two sisters, aged 5 and 3 years, who developed cutaneous Pseudomonas aeruginosa after receiving anti-infectives and/or hydrocarbon emollients.

  • In the Literature.  // Clinical Infectious Diseases;Oct2013, Vol. 57 Issue 8, piii 

    Reviews of two articles "Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections" by K.A. Bauer, J.E. West, J.M. O'Brien and D.R. Goff, which appeared in the periodical "Antimicrob Agents Chemotherapy" in 2013, and "Bacteriophage adhering to mucus provide...

  • High mortality rate from infection with P. aeruginosa.  // Nursing Standard;2/24/2010, Vol. 24 Issue 25, p16 

    The article presents results from a study which investigated the mortality rate of patients infected with pseudomonas aeruginosa.

  • PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Chiarini, M; Sabelli, C; Melotti, P; Garlanda, C; Savoldi, G; Mazza, C; Padoan, R; Plebani, A; Mantovani, A; Notarangelo, L D; Assael, B M; Badolato, R // Genes & Immunity;Dec2010, Vol. 11 Issue 8, p665 

    Cystic fibrosis (CF) is a common life-threatening autosomal recessive disorder in the Caucasian population, and the gene responsible is the CF transmembrane conductance regulator (CFTR). Patients with CF have repeated bacterial infection of the airways caused by Pseudomonas aeruginosa (PA),...

  • Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Tumbarello, Mario; Pascale, Gennaro; Trecarichi, Enrico; Spanu, Teresa; Antonicelli, Federica; Maviglia, Riccardo; Pennisi, Mariano; Bello, Giuseppe; Antonelli, Massimo // Intensive Care Medicine;Apr2013, Vol. 39 Issue 4, p682 

    Purpose: Our aim was to identify the clinical profile of intensive care unit (ICU) patients with Pseudomonas aeruginosa (PA) pneumonia and the impact on ICU mortality and duration of mechanical ventilation (MV) of multidrug resistance (MDR) in the PA isolate and inadequate initial antibiotic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics